Hi, what are you looking for?
By Dean Seal
Orchestra BioMed has gotten the go-ahead from federal regulators to start a study examining BackBeat, its atrioventricular interval modulation therapy for treating hypertension in pacemaker patients.
The biomedical company said Tuesday that the U.S. Food and Drug Administration has granted approval of an investigational device…
Read the full article here
Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...
This article was written by Follow I am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk...
Watch full video on YouTube
